




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, G01N 33/68, A61K 38/17		A1	(11) International Publication Number: WO 00/29569
			(43) International Publication Date: 25 May 2000 (25.05.00)
(21) International Application Number: PCT/EP99/08744 (22) International Filing Date: 12 November 1999 (12.11.99) (30) Priority Data: 98121478.6 12 November 1998 (12.11.98) EP (71)(72) Applicants and Inventors: NITSCH, Roger [DE/CH]; Gugger Strasse 19, CH-8702 Zollikon (CH). GREEVE, Isabell [DE/DE]; Oberstrasse 108, D-20143 Hamburg (DE). (74) Agents: MEYERS, Hans-Wilhelm et al.; P.O. Box 10 22 41, D-50462 Cologne (DE).			(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: METHODS OF DIAGNOSING OR TREATING NEUROLOGICAL DISEASES

Expression of Seladin-1 in different human brain regions



(57) Abstract

The invention discloses an isolated nucleic acid molecule encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein comprises the sequence shown in SEQ ID NO. 2 or functional variant thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS OF DIAGNOSING OR TREATING NEUROLOGICAL DISEASES

Cell death is a common feature occurring in two distinct forms in nature. Necrosis results from physical or chemical insult while apoptosis or programmed cell death results from a self-destruction program within the cell in response to internal and external stimuli. Latter process is a gene-directed form of cell death that is essential for normal development and maintenance of multicellular organisms. Recent work has clearly demonstrated that dysregulation of apoptosis may underlie the pathogenesis of a variety of diseases. Apoptosis has been reported to occur in conditions characterized by ischaemia, e.g. myocardial infarction and stroke. It has been implicated in a number of liver disorders including obstructive jaundice. Hepatic damage due to toxins and drugs is also associated with apoptosis in hepatocytes. Apoptosis has also been identified as a key phenomenon in some diseases of the kidney, i.e. polycystic kidney, as well as in disorders of the pancreas like alcohol-induced pancreatitis and diabetes. AIDS and neurodegenerative disorders like Alzheimer's and Parkinson's disease represent the most widely studied group of disorders where an excess of apoptosis has been implicated. Amyotrophic lateral sclerosis, retinitis pigmentosa, epilepsy and alcoholic brain damage are other neurological disorders in which apoptosis has been implicated.

Neurological diseases are widely spread within a population and have a strong impact not only on patients' life but also on society as such. Therefore, there is a strong need to elucidate the causes and the underlying pathogenesis of such neurological diseases. Among such neurological diseases, Alzheimer's disease (AD) has a predominant position. Alzheimer's disease, first described by the Bavarian psychiatrist Alois Alzheimer in 1907, is a progressive neurological disorder which begins with short term memory loss and proceeds to loss of cognitive functions, disorientation, impairment of judgement and reasoning and, ultimately, dementia. It is the most common cause of dementia. AD has been estimated to afflict 5 to 11 percent of the population over age 65 and as much as 47 percent of the population over age 85. Moreover, as adults, born during the population boom of the 1940's and 1950's, approach the age when AD becomes more prevalent, the control and treatment of AD will become an even more

CONFIRMATION COPY

significant health care problem. Familial forms of AD are genetically heterogeneous, but most with early onset are linked to mutations in the presenilin genes *PSEN1* and *PSEN2*, as well as to mutations of the amyloid precursor gene *APP*. The majority of AD patients have no obvious family history and are classified as sporadic AD. The neuropathology of AD is characterized by a substantial loss of neurons and synapses, and by the formation in brain of amyloid plaques and neurofibrillary tangles. Amyloid plaques are evenly distributed throughout the neocortex and the hippocampus, whereas neurodegeneration occurs predominantly in the inferior temporal lobes, the entorhinal cortex, and the hippocampus. Similar neurons in the frontal, parietal, and occipital lobes are largely preserved from degeneration even in severe end-stage AD. These observations indicate selective vulnerability of specific population of neurons. Factors that determine selective vulnerability of neurons in AD brains are unknown.

To elucidate the causes of cell degeneration and cell death is a general aim of the present invention. More specifically, the present invention aims at elucidating the causes and the underlying pathogenesis of neurological diseases, in particular Alzheimer's disease. It is therefore an object of the present invention to provide an insight into the pathogenesis of neurological diseases and to provide methods and materials which are suited for diagnosis and treatment of said diseases, cell degeneration and cell death.

The invention features an isolated nucleic acid molecule encoding a protein molecule whose amino acid sequence comprises the sequence shown in SEQ ID NO. 1 as well as the protein molecule according to SEQ ID NO.1. Hereinafter, the protein molecule of SEQ ID NO. 1 is denoted "SELADIN-1". One function of SELADIN-1 is to protect cells against degeneration and cell death. In particular, cells of the nerve system, muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta are protected against degeneration and/or cell death. Therefore, the present invention also features functional variants of SELADIN-1 which might have a modification of the given primary structure of SELADIN-1, but whose essential biological function remains unaffected. "Variants" of a protein molecule shown in SEQ ID NO.1 include for example proteins with conservative amino acid substitutions

in highly conservative regions. For example, isoleucine, valine and leucine can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be substituted for each other. Serine and threonine can be substituted for each other. Amino acid substitutions in less conservative regions include e.g.: Isoleucine, valine and leucine can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be substituted for each other. Serine and threonine can be substituted for each other. Glycine and alanine can be substituted for each other. Alanine and valine can be substituted for each other. Methionine can be substituted for each of leucine, isoleucine or valine, and vice versa. Lysine and arginine can be substituted for each other. One of aspartate and glutamate can be substituted for one of arginine or lysine, and vice versa. Histidine can be substituted for arginine or lysine, and vice versa. Glutamine and glutamate can be substituted for each other. Asparagine and aspartate can be substituted for each other. Other examples of protein modifications include glycosilation and further posttranslational modifications. The invention also features the nucleic acid molecules encoding such functional variants of the protein molecule of SEQ ID NO. 1. Nucleic acid molecules can be DNA molecules, such as genomic DNA molecules or cDNA molecules, or RNA molecules, such as mRNA molecules. In particular, said nucleic acid molecule can be a cDNA molecule comprising a nucleotide sequence of SEQ ID NO. 2. The invention also features an isolated D N A molecule capable of hybridizing with the complement of the cD N A described in SEQ ID NO. 2 under stringent conditions. Examples for stringent conditions include (i) 0.2xSSC (standard saline citrate) and 0.1 % SDS at 60 °C and (ii) 50 % formamide, 4xSSC, 50 mM HEPES, pH 7.0, 10x Denhardt's solution, 100 µg/ml thermally denatured salmon sperm DNA at 42 °C.

In another aspect, the invention features a vector comprising a nucleic acid encoding a protein molecule shown in SEQ ID NO. 1. It also features a vector comprising a nucleic acid molecule encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO. 1 or a functional variant thereof. In preferred embodiments, a virus, a bacteriophage, or a plasmid comprises the

described nucleic acid. In particular, a plasmid adapted for expression in a bacterial cell comprises said nucleic acid molecule, e.g. a nucleic acid molecule encoding a protein molecule shown in SEQ ID NO. 1, and the regulatory elements necessary for expression of said molecule in the bacterial cell. In a further aspect, the invention features a plasmid adapted for expression in a yeast cell which comprises said nucleic acid molecule, e.g. a nucleic acid molecule encoding a protein molecule shown in SEQ ID NO. 1, and the regulatory elements necessary for expression of said molecule in the yeast cell. In another aspect, the invention features a plasmid adapted for expression in a mammalian cell which comprises a nucleic acid molecule, e.g. a nucleic acid molecule encoding a protein molecule shown in SEQ ID NO.1, and the regulatory elements necessary for expression of said molecule in the mammalian cell.

In a further aspect, the invention features a cell comprising a nucleic acid molecule encoding a protein molecule shown in SEQ ID NO. 1. The invention also features cells comprising a nucleic acid molecule encoding a protein molecule whose function is to protect cells against degeneration and/or cell death and whose amino acid sequence comprises the sequence shown in SEQ ID NO. 1 or a functional variant thereof. It also features cells comprising a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions. In preferred embodiments, said cell is a bacterial cell, a yeast cell, a mammalian cell, or a cell of an insect. In particular, the invention features a bacterial cell comprising a plasmid adapted for expression in a bacterial cell, said plasmid comprising a nucleic acid molecule which encodes a protein molecule shown in SEQ ID NO. 1, and the regulatory elements necessary for expression of said molecule in the bacterial cell. The invention also features a yeast cell comprising a plasmid adapted for expression in a yeast cell, said plasmid comprises a nucleic acid molecule encoding a protein molecule shown in SEQ ID NO. 1, and the regulatory elements necessary for expression of said molecule in the yeast cell. It further features a mammalian cell comprising a plasmid adapted for expression in a mammalian cell, said plasmid comprising a nucleic acid molecule which encodes a protein molecule shown in SEQ ID NO.1, and the regulatory elements necessary for expression of said molecule in the mammalian cell.

The invention further features an antibody specifically immunoreactive with an immunogen, wherein said immunogen is shown in SEQ ID NO. 1 or wherein said immunogen is a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO. 1 or a functional variant thereof. In another aspect, the invention aims at a method of detecting pathological cells in a subject which comprises immunocytochemically staining cells with the aforementioned antibody, wherein a low degree of staining in said cell compared to a reference cell representing a known health status indicates a pathological change of said cell. The invention is particularly suited to detect pathological structures in the brain of a subject – the detection method comprises immunocytochemically staining said pathological structures with said antibody. It is also especially suited to detect pathological cells of the muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta.

In another aspect, the invention features a method of diagnosing or prognosing a disease, in particular a neurological disease, in a subject comprising:
determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby diagnosing or prognosing a disease, in particular a neurological disease, in said subject.

In another aspect, the invention features a method of monitoring the progression of a disease, in particular a neurological disease, in a subject, comprising:

determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby monitoring progression of a disease, in particular a neurological disease, in said subject.

In still a further aspect, the invention features a method of evaluating a treatment for a disease, in particular a neurological disease, in a subject, said method comprising:

determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby evaluating a treatment for a disease, in particular a neurological disease, in said subject.

In a further aspect, the invention features a kit for diagnosis, or prognosis of a disease, said kit comprising:

- (1) at least one reagent which is selected from the group consisting of reagents that selectively detect
 - (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
 - (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
 - (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
 - (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),
- (2) instructions for diagnosing, or prognosing said disease by
- (i) detecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) in a sample from said subject;
- and
- (ii) diagnosing, or prognosing said disease, wherein a varied level, or activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) similar or equal to a reference value representing a known disease status indicates diagnosis, or prognosis of said disease.

In a further aspect, the kit may be used in monitoring success or failure of a therapeutic treatment of said subject. It can also be used in monitoring the progression of a disease.

Preferred embodiments of the above mentioned methods and kit of diagnosing or prognosing diseases, or monitoring the progression thereof, or evaluating a treatment thereof, are now disclosed in detail.

In a preferred embodiment, the function of said protein molecule or a functional variant thereof is to protect cells from degeneration and/or cell death.

In another preferred embodiment, said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, the function of which is to protect cells against cell degeneration and/or cell death.

In preferred embodiments, said subjects suffer from Alzheimer's disease and related neurofibrillary disorders, or degenerative states, e.g. neurodegenerative states, characterized by cell degeneration or cell death. Further examples of neurological diseases are Parkinson's disease, Huntington disease, amyotrophic lateralsclerosis and Pick's disease.

It is particularly preferred that said sample is a brain tissue or other body cells including cells of the muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea, or placenta. The sample might also be cerebrospinal fluid or another body fluid.

According to the present invention, a reduction in the level, or activity, or both said level and said activity, of (i) a transcription product of a D N A molecule encoding a protein molecule, whose amino acid sequence comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof or (ii) a protein molecule whose amino acid sequence comprises the sequence shown in SEQ ID NO. 1 or a functional variant thereof, in a sample from said subject relative to a reference value representing a known health status indicates the presence of a pathological status in said subject. In particular, a reduction in the level, or activity, or both said level and said activity of SELADIN-1 or *SELADIN-1* transcripts in said subject's brain regions affected heavily by neurodegeneration relative to a reference value representing a known health status indicates a diagnosis or prognosis of Alzheimer's disease. Predominantly neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus and the amygdala degenerate in Alzheimer's disease.

It might be preferred that said subject has previously been determined to have one or more factors indicating that such subject is afflicted with a disease under study, in particular a neurological disease.

In preferred embodiments, said subject can be a human, an experimental animal, e.g. a rat or a mouse, a domestic animal, or a non-human primate, e.g. a monkey. The experimental animal can be an animal model for a disorder, e.g. a transgenic mouse with an Alzheimer's-type neuropathology.

In preferred embodiments, at least one of said substances is detected using an immunoassay, an enzyme activity assay and/or a binding assay.

In preferred embodiments, measurement of the level of transcription products of the *SELADIN-1* gene, or a functional variant thereof, is performed in body cells using Northern blots with probes specific for the *SELADIN-1* gene or said variant. Quantitative PCR with primer combinations to amplify *SELADIN-1* gene-specific sequences from cDNA obtained by reverse transcription of RNA extracted from body cells of a subject can also be applied. These techniques are known to those of ordinary skill in the art (see e.g. Watson et al., *Rekombinierte DNA*, 2nd edition, Spektrum Akademischer Verlag GmbH, Heidelberg, 1993; Watson et al., *Recombinant DNA*, 2nd ed. W.H. Freeman and Company, 1992).

In preferred embodiments, said level or activity of the protein molecule shown in SEQ ID NO. 1, or a functional variant or fragment thereof, is detected using an immunoassay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody, e.g. an anti-*SELADIN-1* antibody, by the use of enzymatic, chromodynamic, radioactive, or luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs, Western blots and other techniques known to those of ordinary skill

in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

The antibody or ligand to be used should preferably specifically detect SELADIN-1 or a functional variant or fragment thereof. It is preferred that it does not substantially interact with any other protein present in said sample.

Monoclonal antibodies capable of recognizing a protein molecule of SEQ ID NO. 1 or a functional variant or fragment thereof can be prepared using methods known in the art (see e.g. Köhler and Milstein, *Nature* 256, 495 - 497 1975; Kozbor et al., *Immunol. Today* 4, 72, 1983; Cole et al., *Monoclonal antibodies and cancer therapy*, Alan R. Liss, Inc., pp 77 - 96, 1985; Marks et al., *J. Biol. Chem.*, 16007 - 16010, 1992; the contents of which are incorporated herein by reference). Such monoclonal antibodies or fragments thereof can also be produced by alternative methods known to those of skill in the art of recombinant DNA technology (see e.g. Sastry et al, *PNAS* 86: 5728, 1989; ; Watson et al., *Rekombinierte DNA*, 2nd ed., Spektrum Akademischer Verlag GmbH, 1993; Watson et al, *Recombinant DNA*, 2nd ed., W. H. Freeman and Company, 1992; the contents of which are incorporated herein by reference). Monoclonal antibodies useful in the methods of the invention are directed to an epitope of SELADIN-1 or a functional variant or fragment thereof, such that the complex formed between the antibody and SELADIN-1, or between the antibody and said functional variant or fragment, can be recognized in detection assays. The term "antibodies" encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, single chain antibodies as well as fragments thereof which specifically bind to SELADIN-1, or to a functional variant or fragment thereof.

Antibodies or ligands might also be used in detecting specifically molecules mentioned in the above described methods and kit under g) and h) above.

If luminescent labels are used in any detection assay, it is preferred to use a confocal optical set-up.

In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) described above in a sample from a subject not suffering of the disease under study, in particular a neurological disease such as Alzheimer's disease. The healthy subject can be of the same weight, age, and gender as the subject who is being diagnosed or prognosed for said disease. In some cases, it might be preferred to use a reference value from the subject which is diagnosed.

In a preferred embodiment, the level, or the activity, or both said level and said activity, of at least one of said substances (a) to (h) described above in a sample is determined at least twice, e.g. at two points which are weeks or months apart. The levels or activities at these two time points are compared in order to monitor the progression of said disease. It might be preferred to take a series of samples over a period of time. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings.

In another aspect, the invention features a method of treating or preventing a disease, in particular a neurological disease, in a subject comprising administering to said subject in a therapeutically effective amount an agent or agents which affect a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

In a preferred embodiment, the function of said protein molecule or a functional variant thereof is to protect cells from degeneration and/or cell death.

In another preferred embodiment, said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, the function of which is to protect cells against cell degeneration and/or cell death.

In preferred embodiments, said subjects suffer from Alzheimer's disease and related neurofibrillary disorders, or degenerative states, such as neurodegenerative states, characterized by cell degeneration or cell death. Further examples of neurological diseases are Parkinson's disease, Huntington disease, amyotrophic lateralsclerosis and Pick's disease.

In preferred embodiments, the method comprises the application of per se known methods of gene therapy nucleic acid technology to administer said agent or said agents.

In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein,

and modulation of endogeneous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, Acc. Chem. Res. 26, 274 - 278, 1993; Mulligan, Science 260, 926 - 931, 1993; the contents of which are incorporated herein by reference) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane perturbation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, Current Opinion in Neurobiology, 3, 743 - 748, 1993; the contents of which are incorporated herein by reference).

In preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, said subject or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically mediated transfection, in particular calcium phosphate transfection, liposomal mediated transfection, etc.

In preferred embodiments, said agent is a therapeutic protein which can be administered to said subject, preferably a human, by a process comprising introducing subject cells into said subject, said subject cells having been treated *in vitro* to insert a DNA segment encoding said therapeutic protein, said subject cells expressing *in vivo* in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells *in vitro* by a viral vector, in particular a retroviral vector.

In preferred embodiments, the therapeutic nucleic acid or protein reduces or prevents the degeneration of cells, in particular neurons and slows brain amyloid formation.

In another aspect, the invention features an agent which affects an activity, or level, or both said activity or level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

Preferably, the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death. Preferably, said D N A molecule capable of

hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein, whose function is to protect cells from degeneration and/or cell death.

In another aspect, the invention features a medicament comprising such an agent.

In still another aspect, the invention features an agent for treating or preventing a disease, in particular a neurological disease, which agent affects an activity, or level, or both said activity or level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

In preferred embodiments, said diseases are degenerative states characterized by cell degeneration or cell death or Alzheimer's disease and related neurofibrillary disorders. Further examples of neurological diseases are Parkinson's disease, Huntington disease, Amyotrophic lateral sclerosis, Pick's disease.

Preferably, the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death. Preferably, said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein, whose function is to protect cells from degeneration and/or cell death.

In a further aspect, the invention features the use of an agent, for preparation of a medicament for treating or preventing a neurological disease, which agent affects an activity, or level, or both said activity or level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (h) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

Preferably, the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death. Preferably, said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO.2 encodes a protein molecule, whose function is to protect cells against degeneration and/or cell death.

In preferred embodiments, said diseases are Alzheimer's disease and related neurofibrillary disorders, or degenerative states, in particular neurodegenerative states, characterized by cell degeneration or cell death. Further examples of neurological diseases are Parkinson's disease, Huntington disease, Amyotrophic lateralsclerosis, Pick's disease.

In a further aspect, the invention features a method for identifying an agent that affects an activity, or level, or both said activity or level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,

- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

comprising the steps of:

- (i) providing a sample containing at least one substance which is selected from the group consisting of (a) to (f),
- (ii) contacting said sample with at least one agent,
- (iii) comparing an activity, or level, or both said activity and level, of at least one of said substances before and after contacting.

Preferably, the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death. Preferably, said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, whose function is to protect cells against degeneration and/or cell death.

Other features and advantages of the invention will be apparent from the following detailed description of the figures, the examples and the claims.

Figure 1 depicts the selective vulnerability of brain regions in Alzheimer's disease. Predominantly neurons within the inferior temporal lobe, the entorhinal cortex, the

hippocampus and the amygdala degenerate in Alzheimer's disease (Terry et al., Annals of Neurology, 10, 184-192, 1981). These brain regions are predominantly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex and the cerebellum are largely intact and preserved from the neurodegenerative process in Alzheimer's disease.

Figure 2 discloses the identification of genes differentially expressed in brain regions from Alzheimer's disease patients. Brain areas with massive neuronal cell loss as well as areas with largely preserved neurons were identified and RNA extracted. Synthesis of cDNA was performed using an oligo-dT primer followed by PCR using the oligo-dT primer in combination with random primers and ($\alpha^{35}\text{S}$)-dATP. Reactions were separated on DNA sequencing gels, DNA bands visualized by autoradiography and bands lighting up in different intensities were cut out. DNA fragments were reamplified by PCR, cloned in *E. coli* and sequences determined. Expression and functional analyses were performed.

Figure 3 depicts the specifications of Alzheimer's disease brain tissue as it was used in the examples. Brain tissues from Alzheimer's disease patients and control subjects were removed within 6 hours of death, and immediately frozen on dry ice. For RNA extraction tissue sections from the inferior temporal lobe and frontal cortex were chosen.

Figure 4 discloses the quantification of *SELADIN-1* transcripts in brain tissue from Alzheimer's disease and control subjects by Northern blot analyses. Transcript levels were significantly lower in brain regions with severe neurodegeneration, i. e. temporal lobe in Alzheimer's disease (AD1-3) but not in normal brain (NB1-3), as compared to protected brain regions, i. e. frontal lobe. This decrease was specific as indicated by unchanged β -actin transcript levels used to control for equal loading of RNA.

Figure 5 depicts the transcription levels of the *SELADIN-1* gene in different human brain regions. The *SELADIN-1* gene was found to be expressed throughout the human brain. In particular transcription levels are high in all cortical areas, the hippocampus, the

amygdala, the spinal cord, and the medulla. Note the unchanged levels in temporal lobe versus frontal lobe in this brain derived from a cognitively normal control subject without any signs of Alzheimer's disease. The analysis of β -actin transcripts was used as loading control.

Figure 6 depicts the distribution of *SELADIN-1* transcripts in human tissues. Comparable samples of RNA were spotted on nitrocellulose filters and *SELADIN-1* transcripts were quantified by hybridization using a labeled *SELADIN-1* gene specific probe. Significant levels of *SELADIN-1* gene transcripts were found in all brain regions tested. Transcripts were also detected in other tissues, however, strong variations in signal intensity indicated a tissue specific regulation of *SELADIN-1* expression.

Figure 7 depicts the expression of the *SELADIN-1* gene in rat brain cortex, hippocampus and basal nucleus analyzed by in situ hybridization. This staining pattern along with the higher magnifications indicate that *SELADIN-1* is predominantly expressed in neurons. No significant hybridization signals were observed with glial cells.

Figure 8 depicts the expression of *SELADIN-1* in rat brain nuclei. Strong *SELADIN-1* expression was found in the oculomotor, paraventricular, red and facial nuclei. Higher magnifications indicate predominant hybridization with neurons. No significant hybridization signals were observed with glial cells.

Figure 9 depicts the expression of *SELADIN-1* in rat brain hippocampus and substantia nigra. In situ hybridization with *SELADIN-1* transcripts was detected by photoemulsion autoradiography, confirming the neuron specific expression of this gene.

Figure 10 discloses the subcellular localization of a *SELADIN-1*-EGFP (enhanced green fluorescent protein) fusion in transfected cos cells. The confocal micrographs show the co-localization of the *SELADIN-1*-EGFP fusion with the golgi specific stain BODIPY TR ceramide indicating localization of *SELADIN-1* in the Golgi apparatus and the endoplasmic reticulum.

Figure 11 discloses that the SELADIN-1-EGFP fusion does not localize to mitochondria in transfected cos cells in spite of a putative mitochondrial targeting sequence close to the N-terminus of the SELADIN-1 protein. The confocal micrographs show the different staining patterns caused by the SELADIN-1-EGFP fusion and the specific mitochondrial stain Mito Tracker Red CM-H₂XRos.

Figure 12 discloses structural features of the SELADIN-1 protein based on multiple sequence alignments and secondary structure predictions. Near the N-terminus the SELADIN-1 protein contains a putative mitochondrial localization signal that appears to be inactive in transfected cos cells or when used in EGFP fusions. The central region of the protein contains a sequence that is homologous to a family of oxidoreductases and that contains a FAD site for covalent binding. The protein is predicted to contain five transmembrane regions. The expression in neurons, the co-localization in the Golgi apparatus and the endoplasmic reticulum of the SELADIN-1 protein, the amyloid precursor protein (APP) and the presenilins PS1 and PS2 and furthermore the transmembrane character suggest a functional relationship between these proteins. Mutations in both APP and presenilins were shown to cause an increase in the production of β -amyloid. In a similar way the SELADIN-1 protein might be involved in common biological pathways influencing the processing of the amyloid precursor protein and the generation of A β . Using the SELADIN-1 protein as a probe, interaction partners can be identified which might represent new AD drug targets.

Figure 13 discloses the protein sequence of SELADIN-1 (SEQ ID NO. 1). The full length protein consists of 516 amino acid residues. The sequence is given in the one letter amino acid code.

Figure 14 discloses the nucleotide sequence of the cloned *SELADIN-1* cDNA (SEQ ID NO. 2) comprising 4248 nucleotides. The coding sequence for the SELADIN-1 protein starts at nucleotide position 100 and stops at position 1648.

Figure 15 discloses the comparison of nucleotide sequences of the cloned *SELADIN-1* cDNA comprising 4248 nucleotides and the KIAA0018 cDNA comprising 4186

nucleotides. A significant difference exists at position 1228 of the *SELADIN-1* sequence where a C nucleotide (C/G basepair) is missing in the *KIAA0018* sequence. This results in a frameshift in the open reading frame in the *KIAA0018* sequence relative to the *SELADIN-1* sequence. The consequence is that the translation product of the *KIAA0018* gene is 390 amino acids in length compared to 516 amino acid residues of the *SELADIN-1* translation product. In addition to the difference in length, the frameshift causes a difference between the C-terminal 14 amino acids of the *KIAA0018* protein and the corresponding sequence area of the *SELADIN-1* polypeptide (pos. 377 - 390). The coding sequence for the *SELADIN-1* protein starts at nucleotide position 100 and stops at position 1648.

Figure 16 shows the amino acid sequence of *SELADIN-1*. A differential display approach (von der Kammer, H. et al., Nucleic acid research, 27, 2211, 1999; von der Kammer, H. et al., J. Biol. Chem. 273, 14538, 1998) to identify genes that are differentially expressed in selectively vulnerable cell populations in the inferior temporal cortex with confirmed neurodegeneration and in the largely unaffected frontal or sensory-motor cortex of the same subject in three brains with a histopathological diagnosis of Alzheimer's disease and post mortem time intervals of less than four hours. By using forty different primer combinations, twenty-eight of thirty-six differentially expressed cDNAs were cloned and sequenced. These cDNAs were further analyzed by reverse Northern blotting (Poirier G.M.-C. et al., Nucleic Acid Res., 25, 913, 1997; Van Gelder R. N. et al., Proc. Natl. Acad. Sci. USA, 87, 1663, 1990) to confirm differential expression between the two AD brain regions. Expression of one of these cDNAs was markedly lower in the inferior temporal lobe than in the sensory-motor cortex. Therefore, the potential importance of this transcript for the selective vulnerability in AD brain has been investigated. The cDNA sequence consisted of 4248 nucleotides and encoded an open reading frame of 516 amino acid residues. Due to a cytidine insertion at nucleotide position 1167, this sequence differed from the much shorter coding region of its homolog *KIAA0018* deposited in GenBank (Nomura et al., D N A Res. 1, 27, 1994; GenBank database accession HUMRSC390D13643,1, 1992; DIMH Human Q15392, 1998). The new gene has been designated *SELADIN-1*. The homology domain to oxido-reductases are highlighted in red; the homologies to "diminuto like proteins" of

other species are underlined. The first 21 amino acid residues represent a putative signal peptide. One possible caspase recognition motif is highlighted in yellow. This putative caspase recognition motif "LEVD" is present within the SELADIN-1 amino acid sequence at position 121 – 125. *In vitro* cleavage of SELADIN-1 by caspase 3 or 6 generated four different SELADIN-1 fragments of approximately 50, 40, 30 and 20 kDa, respectively. Secondary structure predictions revealed at least four possible transmembrane domains.

Figure 17 shows Northern blots of Alzheimer's disease (AD) brain and normal control brain. In AD brains, the expression of *SELADIN-1* was substantially lower in the inferior temporal lobe compared to the frontal cortex. In contrast, there was no difference in expression between these two regions in normal control brains (Fig. 17 A, B). Thus, the differential expression of *SELADIN-1* between temporal and frontal cortex within individual AD brains initially observed by both differential display and reverse Northern, was independently confirmed in three other patients. *SELADIN-1* is strongly expressed throughout the normal human brain with highest expression in the cortices, in the medulla oblongata and the spinal cord as well as in substantia nigra and the hippocampus (Fig. 17B). **A** 10 µg of total RNA per lane, extracted with Trizol Reagent (Gibco) from the frontal cortex or the inferior temporal cortex of three different AD brains were separated on a 0.8 % formaldehyde-agarose gel and blotted on a Hybond-N+-Nylon Membrane (Amersham). Brain 1: post mortem time interval 3:30 hours, male, 72 years. Brain 2: post mortem time interval 1:30 hours, male, 62 years. Brain 3: post mortem time interval 4 hours, female, 63 years. Control brain: normal brain, post mortem time interval 1:10 hours, female, 80 years. The blots were hybridized with a ³²P-labeled c D N A probe of *Seladin-1* from nucleotide 1 – 3505 and with a ³²P-labeled c D N A control probe of human β-actin as provided by Clontech for the human brain multiple tissue northern blot II and III. **B** Human brain multiple tissue Northern blot II (Clontech 7755-1) and III (Clontech 7750-1) containing 2 µg of polyA+ RNA per lane from 16 different human brain regions. Blots were hybridized with the same probes as described in A.

Figure 18 shows the expression of *Seladin-1* in rat brain. *In situ* hybridization on paraformaldehyde fixed cryostat sections was performed as described by Hartman et al. (Developmental Neuroscience 17, 246, 1995). A 650 bp and a 900 bp fragment of the open reading frame of *Seladin-1* were PCR amplified using the following primer pairs:

1s (76-99) 5' GCG CTT ACC GCG CGG CGC CGC ACC 3' (SEQ ID NO. 3)

1as (749-726) 5' GAC CAG GGT ACG GCA TAG AAC AGG 3' (SEQ ID NO. 4)

3s (803-826) 5' AGA AGT ACG TCA AGC TGC GTT TCG 3' (SEQ ID NO. 5) and

3as (1749-1726) 5' TTC TCT TTG AAA GTG TGG ATC TAG 3' (SEQ ID NO. 6).

PCR fragments were cloned in pGEM-Teasy vector (Promega), cut with EcoRI and cloned in pBluescript KS+. The orientation of the EcoRI cloned fragments was analyzed by PCR. Using the Ambion Maxiscript kit, ³⁵S-UTP labeled antisense and sense riboprobes were generated on NotI and ClaI linearized plasmids with T3 and T7-Polymerase, respectively, according to the manufacturers instructions. Hybridized sections were dipped in NTB-3 photographic emulsion (Kodak), exposed for 5 weeks and counterstained in Mayer's hemalum. **A, D, G** show photomicrographs of the emulsion dipped sections. **pvn** paraventricular nucleus, **bnM** basal nucleus of Meynert, **amy** amygdala, **ocmn** oculomotor nucleus, **rn** red nucleus, **fn** facial nucleus. **B** is a darkfield illumination blow up of the hippocampal region. **dg** dentate gyrus. **C** is a darkfield illumination blow up of the cortical layer five **cl V**. **E, H** show brightfield higher magnification photomicrographes of the regions of interest from D and G. **F, I** DIC (differential interference contrast) illuminations in higher magnification of E and H to demonstrate single neurons stained with silver grains. In rat brain, expression of *SELADIN-1* was high in the hippocampal region CA3 (Fig. 18 A, B), in the pyramidal neurons of cortical layer five (Fig. 18 A, C), in the amygdala (Fig. 18 A), in the magnocellular neurons of the basal nucleus of Meynert (Fig. 18 A) and in the reticular zone of the substantia nigra (data not shown). In addition, transcripts were also detected in several brain nuclei including the paraventricular nucleus (Fig. 18 A), the oculomotor nucleus (Fig. 18 D, E), the facial nucleus (Fig. 18 G, F) as well as the red nucleus (Fig. 18 D, E).

Figure 19 shows *in situ* hybridization of human AD (**A-D**) and normal brain (**E-H**). *In situ* hybridization on embedded sections was performed as described (U. Süsens, Dev. Neurosci. 19, 410, 1997). The ³⁵S-UTP labeled riboprobe was derived from the first 650 nucleotides of the open reading frame of *Seladin-1* cloned in pBluescript KS+ as described in Figure 18. The hybridized slides were dipped in Kodak NTB-2 emulsion, exposed for 4 weeks. After development, sections were stained with Giemsa. **A, C, E and G** show darkfield illuminations and **B, D, F, H** the corresponding brightfield photomicrographes. To enhance the visibility of the silver grains in the brightfield picture higher magnification is shown. **A, B** representative hybridization pattern of *Seladin-1* in midfrontal cortex of AD brain. **C, D** representative hybridization pattern of *Seladin-1* in superior temporal cortex of AD brain. **E, F** representative hybridization pattern of *Seladin-1* in midfrontal cortex of normal brain. **G, H** representative hybridization pattern of *Seladin-1* in superior temporal cortex of normal brain. Arrowheads indicate neurons packed with silver grains; arrows indicate the neurons with only few grains (D). *In situ* hybridization of human AD and control brains to study the expression of *SELADIN-1* within single neurons, demonstrated that *SELADIN-1* mRNA was reduced in the remaining neurons of the temporal cortex in comparison to the neurons in the frontal cortex in the AD brains (Fig. 19, A-D, arrows). In contrast, in normal brains, neuronal expression of *SELADIN-1* was identical between the frontal cortex and the temporal cortex (Fig. 19, E-H, arrowheads), confirming the data from differential display and Northern blot analyses. Reduced levels of *SELADIN-1* mRNA in the temporal cortex in comparison to the frontal cortex in the AD brain were not only due to cell loss but were also reduced within the remaining neurons.

Figure 20. To analyze SELADIN-1 function as a putative oxido-reductase, human H4 neuroglioma cells were stably transfected with Seladin-1 fused at its C-terminus to EGFP (enhanced green fluorescence protein, Clontech). **A** 10 and 16 hours after incubation of three seladin-1-EGFP clones and three EGFP-control clones in OptiMEM1 containing 200 µM H₂O₂, cells remaining attached to the culture dish as well as cells in the supernatant were harvested and stained with 7-Amino-actinomycin D (7-ADD) as a standard flow cytometric viability probe to distinguish viable from non viable cells. Only

membranes of dead and damaged cells are permeable to this D N A dye and stain positive. Live/dead counts were done on FACSCalibur (Becton Dickinson) counting 10^5 cells per clone. Means of 2 experiments in triplicate are shown ($\pm$ SEM). All SELADIN-1 expressing clones tolerated H_2O_2 -induced oxidative stress much better than either non-transfected or EGFP expressing clones. After ten hours treatment with 200 μ M H_2O_2 nearly 90 % of the SELADIN-1 expressing cells and 75 – 80 % of the control cells were viable; sixteen hours after incubation with 200 μ M H_2O_2 , however, 80 % of the SELADIN-1 expressing cells were still alive whereas only 52 % of the control cells were alive at this time point. Untreated control clones revealed a maximum of 5 % dead cells at equivalent time intervals. Increased survival rates in SELADIN-1 expressing cells after prolonged exposure to oxidative stress was confirmed by two independent approaches: First, live/dead counts were done on trypan blue stained cells on cell culture dishes and visualized in phase-contrast microscopy in ten randomly chosen fields. Second, nuclei of cells grown on coverslips and fixed with 4 % paraformaldehyde were stained with Hoechst dye 33342 (Molecular Probes) and visualized by fluorescence microscopy (data not shown). These measures confirmed that expression of SELADIN-1 conferred resistance against induction of cell death.

B To determine an early marker for apoptotic cell death, the activity of caspase 3 in cell lysates of three SELADIN-1-EGFP clones and three EGFP-control clones was measured using the caspase 3 assay kit from Pharmingen. After induction of apoptosis with 200 μ M H_2O_2 for 2 or 4 hours, respectively, cells were washed briefly in PBS and lysed in 10 mM Tris-HCl, pH 7.5, 10 mM NaH_2PO_4 , pH 7.5, 130 mM NaCl, 1 % Triton-X-100, 10 nM NaPPI (2 million cells/ml). 50 μ l of the cell lysates were incubated in 200 μ l HEPES buffer for 1 hour at 37 °C with 5 μ g of the caspase 3 fluorogenic substrate Ac-DEBD-CHO in a 96 multiwell plate. The AMC liberated from Ac-DEVD after caspase cleavage was measured on a spectrofluorometer (Spectramax Gemini, Molecular Devices) with an excitation wavelength of 380 nm and an emission wavelength spectrum from 420 – 460 nm. Means of caspase 3 activity, measured in RFU (relative fluorescence units) of two experiments in triplicates are shown ($\pm$ SEM). Two hours after induction of apoptosis with 200 μ M H_2O_2 , caspase 3 activity was not detectable in either SELADIN-1-EGFP clones or in the EGFP-control clones. After 4 hours, however, the activity of caspase 3 strongly increased and was found to be approximately two-fold

higher in three EGFP-control clones as compared to three SELADIN-1-EGFP clones. This increase in caspase 3 activity was blocked in either condition by the caspase inhibitor Ac-DEVD-CHO.

Figure 21 shows the subcellular localization of SELADIN-1. 114 human neuroglioma cells that stable express a fusionprotein of SELADIN-1 with the N-terminus of EGFP (Clontech) were grown on coverslips and fixed in 4 % paraformaldehyde in PBS or treated for 45 minutes with 250 nM of the red fluorescent mitochondrial stain MitoTracker red CM H₂Xros (Molecular Probes) before fixation. After fixation cells that have not been prestained with the MitoTracker were permeabilized in 0.2 % Triton-X 100 in PBS and blocked over night at 4 °C in 5 % low fat milk, 0.1 % Triton-X 100 in PBS. Cells were incubated for 2 hours at room temperature with an monoclonal antibody against the mouse anti-protein disulfide isomerase (antiPDImAb, StressGen Biotechnologies Corp.), a marker for the endoplasmic reticulum, washed and incubated for another hour with an anti-mouse IgG, CY3 labeled secondary antibody (Amersham). Cells were visualized with confocal laser scanning microscopy. **A, D** Subcellular distribution of the green fluorescent SELADIN-1-EGFP fusionprotein. **B** Staining of the endoplasmatic reticulum with the antiPDImAb and the red fluorescent CY3 labeled secondary antibody. **C** Overlay from A and B shows the colocalization of SELADIN-1 with the ER-marker, indicated as yellow fluorescence. **E** Staining of the mitochondria with the red fluorescence MitoTracker CM H₂Xros. **F** Overlay of D and E. These colocalization studies with markers and antibodies against several subcellular organelles indicated that SELADIN-1-EGFP mainly localized to the endoplasmatic reticulum and not to the mitochondria, despote the presence of a putative mitochondrial localization signal at the N-terminus of SELADIN-1.

Taken together a novel gene *SELADIN-1* that has homologies to FAD-dependent oxidoreductases has been identified. It has been shown that it was down-regulated in selectively vulnerable regions of AD brain. *In situ* hybridization of AD brain sections demonstrated that the reduced mRNA levels are not only due to neuronal loss in affected areas but also reflects reduced mRNA expression of the remaining neurons. Expression of *SELADIN-1* in H4 cells conferred resistance to apoptosis by oxidative

stress, yet after execution of apoptosis SELADIN-1 is cleaved at putative caspase cleavage sites and therefore is presumably inactivated. These results indicate that SELADIN-1 is an integral component of the cellular machinery protecting cells, in particular neurons, from oxidative stress. Once oxidative stress becomes overwhelming, SELADIN-1 becomes a target for caspase action in the course of apoptosis. *SELADIN-1* is a good candidate gene for therapeutical intervention to protect cells against degeneration and cell death. It is in particular, a good candidate gene for therapeutical intervention to protect neurons from A β induced cytotoxicity.

EXAMPLE I

Post-mortem Alzheimer's disease brain tissues

Brain tissues from Alzheimer's disease patients and control subjects were removed within 6 hours of death, and immediately frozen on dry ice. Parallel sections were fixed in formaldehyde for histopathological confirmation of the diagnosis and for cell counts. Brain areas with massive neuronal cell loss as well as areas with largely preserved neurons were identified for comparisons of gene expression and stored at -80°C until RNA extractions were performed.

Identification of *SELADIN-1* by differential display PCR

Total RNA from post-mortem brain tissues was prepared by using the RNeasy kit (Qiagen). The RNA preparations were treated with DNase I (Boehringer Mannheim) together with RNasin (Promega) for 30 minutes, followed by phenol extraction, and ethanol precipitation. 0.2 mg of each RNA preparation were transcribed to cDNA by using Expand Reverse Transcriptase (Boehringer Mannheim) with one base ancor primers HT₁₁A, HT₁₁C and HT₁₁G. In the following PCR reaction, the cDNAs were amplified by using HT₁₁A along with the random primers HAP-5 (5'-TGCCGAAGCTTGGAGCTT-3') and HAP3-T (5'-TGCCGAAGCTTTGGTCAT-3'). Taq-polymerase (AmpliTaq, Perkin Elmer Corp.), dGTP, dCTP, and dTTP (Amersham Pharmacia Biotech) and (α^{35} S)-dATP (NEN life science products) were used in a PCR protocol according to Zhao et al. The PCR products were separated on 6% polyacrylamide-urea sequencing gels that were dried subsequently on 3 mm filter paper (Whatman), and X-ray films (Dupont) were exposed for 12 hours.

Cloning and sequencing

Differential bands were excised from the gel, boiled in water for 10 minutes, centrifuged, and cDNAs were precipitated from the supernatant fluids by using ethanol and glycogen/sodiumacetate, followed by dialysis against 10% glycerol for 1 hour through 0.025 mm filters (type VS, Millipore). The dialysates were used as templates for the reamplification reactions that were done under identical conditions as in the differential

display PCR, with the exception of the initial cycle for nonspecific annealing. The resulting PCR products were separated by agarose gelelectrophoresis, purified from the gel with the QIAEXII Agarose Gel Extraction Kit (Qiagen), and cloned into the *Hind* III restriction site of pBluescript KS (Stratagene). Cloned cDNA fragments were sequenced with an ABI 377 DNA sequencer (Perkin Elmer Corp.) by using T3 and T7 primers.

Amplification of a *SELADIN-1* cDNA-fragment

A *SELADIN-1* cDNA fragment was amplified by using cDNA transcribed from human brain tissue by using RNA High Fidelity Taq-polymerase (Boehringer Mannheim) and *SELADIN-1*-specific primers for a PCR reaction with 40 cycles of annealing of 70 °C for 1 minute, and polymerization at 72 °C for 3 minutes. The PCR products were separated by agarose gel electrophoresis, purified, and cloned into the *Sma* I restriction site of pBluescript KS (Stratagene). The cloned PCR product was sequenced, and restriction were used as a probe both for screening a human brain cDNA library and for probing Northern blots.

Northern blotting

Total RNA from post-mortem human brains were prepared by using the Trizol reagent (Gibco BRL, Life Technologies), following the manufacturer's instructions. 5 - 10 mg of RNA were separated in 1 % formaldehyde-containing agarose gels, and the RNA was blotted onto nylon membranes (Hybond-N⁺, Amersham). Membranes were hybridized with (α -³²P)-dCTP (NEN) labeled *SELADIN-1*-specific cDNA probes that were generated by using the Megaprime DNA labelling kit (Amersham). Membranes were washed under high stringency conditions, and X-ray films were exposed for 1 to 72 hours. To control for equal loading of RNA, the identical membranes were probed with a 700 pb cDNA fragment of human glycerolaldehyd-3-phosphate dehydrogenase (*GAPDH*), or with a b-actin cDNA fragment (Clontech).

In situ hybridization

Several *SELADIN-1*-specific cDNA probes of 650bp and of 900bp representing the initial two parts of the open reading frame were cloned in pBluescript (Stratagene) and reversely transcribed in the presence of ^{35}S -CTP by using the Ambion transcription kit. In situ hybridization was done with, 14mm sections of adult rat brain cut on a cryomicrotome, mounted on aminoalkylsilane-treated slides and fixed in 4 % paraformaldehyde in PBS for 5 min at room temperature. After washing for 5 min in PBS, sections were acetylated for 10 min, passed through a series of increasing ethanol grades and air dried. Prehybridizations were done in 50 % deionized formamide, 25 mM EDTA, 25 mM Pipes, pH 6.8, 0.75 M NaCl, 0.2 % SDS, 5 x Denhardt's, 10 mM DTT, 250 mg/ml denatured herring sperm DNA and 250 mg/ml yeast tRNA. Hybridization of slides with RNA sense and antisense probes diluted to 2000 – 5000 cpm/ml in the same buffer with additional 10 % dextransulphate was performed at 50 °C for 12 hours. Slides were then washed four times in 4 x SCC for 5 min. each, followed by an incubation for 30 min. at 37 °C with 40 mg/ml RNaseA in 0.5 M NaCl, 10 mM Tris-HCL, pH 7.5, 1mM EDTA and another 30 min without RNaseA. Then slides were washed twice for 15 min. at 50 °C in 2 x SCC and dried through graded ethanols. Slides were exposed to Kodak Biomax x-ray films for 15 days and subsequently dipped in Kodak NTB-3 nuclear track emulsion and exposed for 6 weeks. After developing in Kodak D19 and fixing in Kodak Unifix, slides were counterstained with Mayer's Hemalaun and coverslipped.

Recombinant expression of SELADIN-1-EGFP fusion proteins in tissue culture

The complete coding region of *SELADIN-1* was subcloned into the N-terminus of the pEGFP-N1-expression vector (Clontech). Cos-7-cells were transfected with *EGFP* or with *SELADIN-1-EGFP* by using the SuperFect transfection reagent from Qiagen according to the manufacturers instructions. Cells were cultured in 3 cm dishes for two days. Part of the cells were stained for the Golgi-apparatus with 0.25 mM BODIPY TR ceramide (molecular probes) for one hour, the other part was treated with 250 nM of the mitochondrial stain Mito Tracker Red CM-H2Xros (Molecular probes) for 45 min. the subcellular localization of the *SELADIN-1-EGFP* fusion protein was analyzed by confocal laser scanning microscopy using the appropriate filter sets.

CLAIMS

1. An isolated nucleic acid encoding a protein molecule shown in SEQ ID NO. 1.
2. An isolated nucleic acid molecule encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof.
3. An isolated nucleic acid molecule of claim 1 or 2, wherein the nucleic acid molecule is a D N A molecule.
4. An isolated nucleic acid molecule of claim 3, wherein the nucleic acid molecule is a cD N A molecule, in particular a cD N A molecule comprising a nucleotide sequence shown in SEQ ID NO. 2.
5. An isolated D N A molecule capable of hybridizing with the complement of the cD N A described in SEQ ID NO. 2 under stringent condition.
6. An isolated D N A molecule of claim 5 encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death.
7. An isolated nucleic acid molecule of claim 2 or 5 encoding a protein molecule, the function of which is to protect cells of the nerve system, muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta against degeneration and/or cell death.
8. A vector comprising a nucleic acid molecule according to one of claims 1 to 7.

9. A vector according to claim 8 wherein said vector is a plasmid, a virus or a bacteriophage.
10. A plasmid according to claim 9 wherein said plasmid is adapted for expression in a yeast cell and further comprises the regulatory elements necessary for expression of said nucleic acid molecule.
11. A plasmid according to claim 9 wherein said plasmid is adapted for expression in a bacterial cell and further comprises the regulatory elements necessary for expression of said nucleic acid molecule.
12. A plasmid according to claim 8 wherein said plasmid is adapted for expression in a mammalian cell and further comprises the regulatory elements necessary for expression of said nucleic acid molecule.
13. A cell transformed with a nucleic acid molecule according to one of claims 1 to 7, wherein said cell is in particular a bacterial cell, a yeast cell, a mammalian cell, or an insect cell.
14. A protein molecule shown in SEQ ID NO.1.
15. A protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof.
16. A protein molecule of claim 14, the function of which is to protect cells of the nerve system, muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, against degeneration and/or cell death.
17. An antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 1.

18. An antibody specifically immunoreactive with a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO. 1 or a functional variant thereof.
19. A method of detecting pathological cells in a subject which comprises immunocytochemically staining cells with an antibody of claim 17 or 18, wherein a low degree of staining in said cell compared to a cell representing a known health status indicates a pathological change of said cells.
20. A method of claim 19, wherein cells of the nerve system, muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta are used.
21. A method of diagnosing or prognosing a disease, in particular a neurological disease, in a subject comprising:
- determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of
- (b) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (c) a protein molecule wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby diagnosing or prognosing a disease, in particular a neurological disease, in said subject.

22. A method of monitoring the progression of a disease, in particular a neurological disease, in a subject, comprising:

determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby monitoring progression of a disease, in particular a neurological disease, in said subject.

23.A method of evaluating a treatment for a disease, in particular a neurological disease, in a subject, said method comprising:

determining a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

and comparing said level, or said activity, or both said level and said activity, of at least one of said substances (a) to (h) to a reference value representing a known disease or health status, thereby evaluating a treatment for a disease, in particular a neurological disease, in said subject.

24. The method according to one of claims 21 to 23, wherein the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death.

25. The method according to one of claims 21 to 24, wherein a decrease of a level or an activity of (i) a transcription product of a D N A molecule encoding a protein molecule, the amino acid sequence of which comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof or (ii) a protein molecule, the amino acid sequence of which comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof, in a sample from said subject relative to a reference value representing a known health status indicates the presence of a disease, in particular a neurological disease, in said subject.

26. The method according to one of claims 21 to 25, wherein said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2

encodes a protein molecule, the function of which is to protect cells against degeneration and/or cell death.

27. The method according to one of claims 21 to 26, wherein said subject suffers from Alzheimer's disease or related neurofibrillary disorders, or neurodegenerative states characterized by cell degeneration or cell death, or Parkinson's disease, or Huntington disease, or Amyotrophic lateralsclerosis or Pick's disease.

28. An agent which affects an activity, or level, or both said activity and level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),

- (h) a molecule which is affected its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

29. An agent of claim 28, wherein the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death.

30. An agent of claim 28 or 29 wherein said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, the function of which is to protect cells against degeneration and/or cell death.

31. A medicament comprising an agent according to one of claims 28 to 30.

32. Use of an agent for preparation of a medicament for treating or preventing a neurological disease, in particular Alzheimer's disease, which agent affects an activity, or level, or both said activity and level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f).

33. Use of an agent according to claim 32, wherein the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death.

34. Use of an agent according to claim 32 or 33, wherein said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, the function of which is to protect cells against degeneration and/or cell death.

35. A method of identifying an agent that affects an activity, or level, or both said activity and level, of at least one substance which is selected from the group consisting of

- (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
- (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,

- (e) a transcription product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (f) a translation product of a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
- (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
- (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),

comprising the steps of:

- (i) providing a sample containing at least one substance which is selected from the group consisting of (a) to (f),
- (ii) contacting said sample with at least one agent,
- (iii) comparing an activity, or level, or both said activity and level, of at least one of said substances before and after contacting.

36.A method of claim 35 wherein the function of said protein molecule or a variant thereof is to protect cells from degeneration and/or cell death.

37.A method of claim 35 or 36 wherein said D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 encodes a protein molecule, the function of which is to protect cells against degeneration and/or cell death.

38.A kit for diagnosis, or prognosis of a disease, said kit comprising:

- (1) at least one reagent which is selected from the group consisting of reagents that selectively detect
 - (a) a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,

- (b) a transcription product of a D N A molecule encoding a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (c) a protein molecule, wherein the amino acid sequence of the protein molecule comprises the sequence shown in SEQ ID NO.1 or a functional variant thereof,
 - (d) a D N A molecule capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
 - (e) a transcription product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
 - (f) a translation product of a D N A molecule, wherein said D N A molecule is capable of hybridizing with the complement of the c D N A described in SEQ ID NO. 2 under stringent conditions,
 - (g) a molecule affecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (f),
 - (h) a molecule which is affected in its level, or its activity, or both its level and activity, by at least one substance which is selected from the group consisting of (a) to (f),
- (2) instructions for diagnosing, or prognosing said disease by
- (i) detecting a level, or an activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) in a sample from said subject;
and
 - (ii) diagnosing, or prognosing said disease, wherein
a varied level, or activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) compared to a reference value representing a known health status;
or a level, or activity, or both said level and said activity, of at least one substance which is selected from the group consisting of (a) to (h) similar or equal to a

reference value representing a known disease status indicates diagnosis, or prognosis of said disease.

Selective vulnerability of brain regions in Alzheimer's disease





Figure 1

Identification of genes differentially expressed in AD brain regions




Figure 2

- 3 / 29 -

Identification of genes differentially expressed in AD brain regions

Material: AD brain tissue
post mortem time intervall <6h
2 different regions histologically characterized
- inferior temporal lobe
- frontal cortex

Method: mRNA differential display screen

Figure 3

Expression of Seladin-1 in AD brain




Figure 4

**Expression of Seladin-1 in different human
brain regions**





Figure 5

Expression of Seladin-1 in human tissues



whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal cortex	hippocampus	medulla oblongata
occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	sub-thalamic nucleus	spinal cord	
heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
appendix	lung	trachea	placenta				
fetal brain	fetal heart	fetal kidney	fetal liver	fetal spleen	fetal thymus	fetal lung	
yeast total RNA 100ng	yeast tRNA 100ng	E. coli rRNA 100ng	E. coli DNA 100ng	Poly r(A) 100ng	human Cot1DNA 100ng	human DNA 100ng	human DNA 500ng

Figure 6

Expression of Seladin-1 in rat brain




Figure 7

Expression of Seladin-1 in rat brain




Figure 8

Expression of Seladin-1 in rat brain




Figure 9

- 10 / 29 -

Subcellular localization of Seladin-1 EGFP fusionprotein




Figure 10

- 11 / 29 -

Subcellular localization of Seladin-1 EGFP fusionprotein

Seladin-1-EGFP Mitochondrial stain
MitoTracker Red CM-H2XRos overlay




Figure 11

Multiple sequence alignments and secondary structure prediction of Seladin-1




Figure 12

- 13 / 29 -

FIGURE 13: SEQ ID NO.1**Seladin-1 amino acid sequence**

Seladin-1.orf Length: 516 May 29, 1998 14:51 Type: P
Check: 1354 ..

```
1   MEPAVSLAVC ALLFLLWVRL KGLEFVLIHQ RWVFVCLFLL PLSLIFDIYY
51  YVRAWVVKL SSAPRLHEQR VRDIQKQVRE WKEQGSKTFM CTGRPGWLTV
101 SLRVGKYKKT HKNIMINLMD ILEVDTKKQI VRVEPLVTMG QVTALLTSIG
151 WTLPLPELD DLTVGGLIMG TGISSSHKY GLFQHICTAY ELVLADGSFV
201 RCTPSSENSDL FYAVPWSCGT LGFLVAAEIR IIPAKKYVKL RFEPVRGLEA
251 ICAKFTHESQ RQENHFVEGL LYSLDEAVIM TGVMTDEAEP SKLNSIGNYY
301 KPWFFKHVEN YLKTNREGLE YIPLRHYYHR HTRSIFWELQ DIIPFGNNPI
351 FRYLFGWMVP PKISLLKLTQ GETLRKLYEQ HHVVQDMLVP MKCLQQALHT
401 FQNDIHVYPI WLCPPFILPSQ PGLVHPKGNE AELYIDIGAY GEPRVKHFEA
451 RSCMRQLEKF VRSVHGFQML YADCYMNREE FWEMFDGSLY HKLREKLGCO
501 DAFPEVYDKI CKAARH
```

- 14 / 29 -

FIGURE 14: SEQ ID NO.2***Seladin-1* cDNA sequence**

Seladin-1 Length: 4248 April 28, 1998 14:10 Type: N Check: 8184 ..

```
1  cccgggctgt gggctacagg cgcagagcgg gccaggcgcg gagctggcgg
51  cagtgcacagg aggcgcgaac ccgcagcgct taccgcgcgg cgccgcacca
101 tggagcccgcg cgtgtcgctg gccgtgtgcg cgctgctctt cctgctgtgg
151 gtgcgcctga aggggctgga gttcgtgctc atccaccagc gctgggtggt
201 cgtgtgcctc ttcctcctgc cgctctcgct tatcttcgat atctactact
251 acgtgcgcgc ctgggtggtg ttcaagctca gcagcgctcc gcgcctgcac
301 gagcagcgcg tgcgggacat ccagaagcag gtgcgggaat ggaaggagca
351 gggtagcaag accttcatgt gcacggggcg ccctggctgg ctactgtct
401 cactacgtgt cggaagtac aagaagacac aaaaaacat catgatcaac
451 ctgatggaca ttctggaagt ggacaccaag aaacagattg tccgtgtgga
501 gcccttggtg accatgggcc aggtgactgc cctgctgacc tccattggct
551 ggactctccc cgtgttgctt gagcttgatg acctcacagt ggggggcttg
601 atcatgggca caggcatcga gtcacatcc cacaagtacg gcctgttcca
651 acacatctgc actgcttacg agctggctct ggctgatggc agctttgtgc
701 gatgcactcc gtccgaaaac tcagacctgt tctatgccgt accctggctc
751 tgtgggacgc tgggtttcct ggtggccgct gagatccgca tcatccctgc
801 caagaagtac gtcaagctgc gtttcgagcc agtgcggggc ctggaggcta
851 tctgtgccaa gttcaccac gagtcccagc ggaggagaa ccacttcgtg
901 gaagggtgc tctactccct ggatgaggct gtcattatga caggggtcat
951 gacagatgag gcagagccca gcaagctgaa tagcattggc aattactaca
1001 agccgtggtt ctttaagcat gtggagaact atctgaagac aaaccgagag
1051 ggcttgaggt acattccctt gagacactac taccaccgcc acacgcgcag
1101 catcttctgg gagctccagg acatcatccc ctttggcaac aacccatct
1151 tccgtacct ctttggctgg atggtgcctc ccaagatctc cctcctgaag
1201 ctgaccagg gtgagaccct gcgcaagctg tacgagcagc accacgtggt
1251 gcaggacatg ctggtgcca tgaagtgcct gcagcaggcc ctgcacacct
1301 tccaaaacga catccacgtc taccocatct ggctgtgtcc gttcatcctg
1351 ccagccagc caggcctagt gcaccccaaa ggaaatgagg cagagctcta
```

- 15 / 29 -

1401 catcgacatt ggagcatatg gggagccgcg tgtgaaacac tttgaagcca
1451 ggtcctgcat gaggcagctg gagaagtttg tccgcagcgt gcatggcttc
1501 cagatgctgt atgccgactg ctacatgaac cgggaggagt tctgggagat
1551 gtttgatggc tccttgtagc acaagctgag agagaagctg ggttgccagg
1601 acgccttccc cgaggtgtac gacaagatct gcaaggccgc caggcactga
1651 gctggagccc gcctggagag acagacacgt gtgagtggtc aggcactctc
1701 ccttcactca agcttggtg ctttcctaga tccacacttt caaagagaaa
1751 cccctccaga actcccaccc tgacagccca acaccacctt cctcctggct
1801 tccagggggc agcccagtg aatggaaaga atgtgggatt tggagtcaga
1851 caagcctgag tccagttccc cgtttagaac tcattagctg tgtgactctg
1901 ggtgagtccc ttaaccctc tgagcccggt tctcttcatt agttgaaagg
1951 gatagtaata cctacttgca ggttggtgtc atctgagttg agcactggtc
2001 acattgaagg tgctgggtaa gtggtagctc ttgttgcttc ccgttcagcg
2051 tcacatctgc agtgagcct gaaaaggctc cacattaggt cacctgtgca
2101 cagccatggc tggaatgatg aaggggatac gctggagttg ccctgccatc
2151 gcctccatca gccagacgag gtcctcacag gagaaggaca gctcttcccc
2201 accctgggat ctgaggagg cagccacgga gtggggaggc cccagatgag
2251 ctgtgccaaa gccaggtccg aggccaaagt tctccctgcc atccttggtg
2301 ccgtcctgcc cttctctcct tcatgcctgg gcctgcaggc ccaccccagc
2351 caccactgag tccactcgga gtgccctgtg ttcttgagga aggcattcca
2401 gggttgaatc ttgtcccagc ctgagcctgg gacacctagg tggagagagt
2451 ggtctccgct ctgaattgga tccaggggac ctgggctcat tcttcttggc
2501 tcaccaaccc tgcaggcctc atctttccca aaaccactt tgtcttggtg
2551 ggagtgggtc cgcgctgctc tgcagcaggg gctggggagt ggacagcatc
2601 aggtgggaaa gtggagtcca ccctcatgtt tctgtaggat tctcacctg
2651 gggctggaag aaaagagcat cgacttgatt tctccaacca ctcatccctc
2701 tttttcttctc ttccaccact cccaccccca gctgtagtta atttcagtgc
2751 cttacaaatc ctaagctcag agaaagtcc atttccgttc cagaggggag
2801 ggaacctccc taggtccttc cctggcttgt tataacgcaa agcttggtg
2851 tttatgcaac tctatcttaa gaactgccca gcctcagctg aaaacccgaa
2901 tctgagaagg aattgctca tgtaagggaa gctggaatta agggagctga
2951 gccagtcatg gttgtggcgt gtgagtcagg agacctaggt ttcagcccct

- 16 / 29 -

3001 ctctactgtc agcgagctgt gcaacgtggg caagtcattg tcctctgagc
3051 tgcagtttcc tcctctgtca catcgctaca gacaagacct ccctggaacc
3101 cttctgattg tcttagacac tgtggttgca aaaccacg aaagcctcat
3151 ttgtgtggaa agtcagagga aaaatgatcc agtggacact tggggattat
3201 ctgtcattca agatccttcc ttcaacccca aggccagctc ccatctcatt
3251 tccagaaaag ctcatacctg gcttgcaggg aagcatctgt cttgtcattc
3301 caggtgccag aatcctctca gagtcattga aggtgttca cccatccac
3351 ccaaggcttg gcacactgcc agtgtcttag caggtcttg tgagggttg
3401 gggcatccag gcactcagaa ggcaaaggaa ccacctacc catttggcct
3451 ctggaggggg cagaagaaag aaagaaacct catcctatat ttacaaagc
3501 atgtgaattc tggcattagc tctcatagga gacctatgtg ctctctgtg
3551 cagtgcacaa ctgatgattc tacttgctgt agatgaatgg ttaacacgag
3601 ctagttaaac agtgccattg ttttgccagt gaagcctcca accctaagcc
3651 actgggacgg tggccagaga tgccagcagc ctctgtcgcc cttagtcata
3701 taacaaaaat ccagacctta tccacaaccc ggggcttga aaggaaggta
3751 ttttggaatc acacctccg gttatgttgc tcagtaaaa tcttgccctg
3801 aaagaggcag tcttcttagc atggtgagct gagttcatgg ctttttttg
3851 tagccagtcc tgtccctggc catccatgtg atggttttg atggagttaa
3901 acttgatgcc agtgggcagt gcatgtggaa agtatcagag taagcctctc
3951 ccctccagag ccctgagttt cttggctgca tgaaggttt ctttagaatc
4001 agaattgtag ccagtttctt tggccagaag gatgaatact tggatattac
4051 tgaaaggag gggaggagat ggggtggca gtgtatggg tgtgatttt
4101 attttcttct ttggctatgg gggccaagga gaaaggcatg aatcttcct
4151 gtcaggctct tacagccaca ggcaactgtg ctactgtctg gaagacatgt
4201 ccccgaggct gtggggccgc tgcttctgtt taaataaaag tggcctgg

- 17 / 29 -

FIGURE 15 CDNA sequence comparison KIAA0018/Seladin-1

```

1  ggcgcgaaacccgcagcgcttaccgcgcggcgccgcacccatggagcccgc 50
   ||||||||||||||||||||||||||||||||||||||||||||||||
62  ggcgcgaaacccgcagcgcttaccgcgcggcgccgcacccatggagcccgc 111
   ||||||||||||||||||||||||||||||||||||||||||||||||
51  gtgtcgctggccgtgtgcgcgctgctcttcctgctgtgggtgcgccctgaa 100
   ||||||||||||||||||||||||||||||||||||||||||||||||
112  gtgtcgctggccgtgtgcgcgctgctcttcctgctgtgggtgcgccctgaa 161
   ||||||||||||||||||||||||||||||||||||||||||||||||
101  ggggctggagttcgtgctcatccaccagcgctgggtgttcgtgtgcctct 150
   ||||||||||||||||||||||||||||||||||||||||||||||||
162  ggggctggagttcgtgctcatccaccagcgctgggtgttcgtgtgcctct 211
   ||||||||||||||||||||||||||||||||||||||||||||||||
151  tcctcctgcccgtctcgccttatcttcgatctactactacgtgcgcgcc 200
   ||||||||||||||||||||||||||||||||||||||||||||||||
212  tcctcctgcccgtctcgccttatcttcgatctactactacgtgcgcgcc 261
   ||||||||||||||||||||||||||||||||||||||||||||||||
201  tgggtggtgttcaagctcagcagcgctccgcgcctgcacgagcagcgct 250
   ||||||||||||||||||||||||||||||||||||||||||||||||
262  tgggtggtgttcaagctcagcagcgctccgcgcctgcacgagcagcgct 311
   ||||||||||||||||||||||||||||||||||||||||||||||||
251  gcgggacatccagaagcaggtgcgggaatggaaggagcagggtagcaaga 300
   ||||||||||||||||||||||||||||||||||||||||||||||||
312  gcgggacatccagaagcaggtgcgggaatggaaggagcagggtagcaaga 361
   ||||||||||||||||||||||||||||||||||||||||||||||||
301  ccttcattgtgcacggggcgccctggctggctcactgtctcactacgtgtc 350
   ||||||||||||||||||||||||||||||||||||||||||||||||
362  ccttcattgtgcacggggcgccctggctggctcactgtctcactacgtgtc 411
   ||||||||||||||||||||||||||||||||||||||||||||||||
351  gggaagtacaagaagacacacaaaaacatcatgatcaacctgatggacat 400
   ||||||||||||||||||||||||||||||||||||||||||||||||
412  gggaagtacaagaagacacacaaaaacatcatgatcaacctgatggacat 461
   ||||||||||||||||||||||||||||||||||||||||||||||||
401  tctggaagtggacaccaagaacagattgtccgtgtggagcccttggtga 450
   ||||||||||||||||||||||||||||||||||||||||||||||||
462  tctggaagtggacaccaagaacagattgtccgtgtggagcccttggtga 511
   ||||||||||||||||||||||||||||||||||||||||||||||||
451  ccatggggccaggtgactgccctgctgacctccattggctggactctcccc 500
   ||||||||||||||||||||||||||||||||||||||||||||||||
512  ccatggggccaggtgactgccctgctgacctccattggctggactctcccc 561
   ||||||||||||||||||||||||||||||||||||||||||||||||
501  gtgttgccctgagcttgatgacctcacagtggggggcttgatcatgggcac 550
   ||||||||||||||||||||||||||||||||||||||||||||||||
562  gtgttgccctgagcttgatgacctcacagtggggggcttgatcatgggcac 611
   ||||||||||||||||||||||||||||||||||||||||||||||||
551  aggcacgcagtcacatcccacaagtacggcctgttccaacacatctgca 600
   ||||||||||||||||||||||||||||||||||||||||||||||||
612  aggcacgcagtcacatcccacaagtacggcctgttccaacacatctgca 661
   ||||||||||||||||||||||||||||||||||||||||||||||||
601  ctgcttacgagctggctcctggctgatggcagctttgtgcatgcaactccg 650
   ||||||||||||||||||||||||||||||||||||||||||||||||
662  ctgcttacgagctggctcctggctgatggcagctttgtgcatgcaactccg 711
   ||||||||||||||||||||||||||||||||||||||||||||||||
651  tccgaaaactcagacctgttctatgccgtaccctggctcctgtgggacgct 700
   ||||||||||||||||||||||||||||||||||||||||||||||||
712  tccgaaaactcagacctgttctatgccgtaccctggctcctgtgggacgct 761
   ||||||||||||||||||||||||||||||||||||||||||||||||
701  gggtttcctgggtggccgctgagatccgcatcatccctgccaagaagtacg 750
   ||||||||||||||||||||||||||||||||||||||||||||||||
762  gggtttcctgggtggccgctgagatccgcatcatccctgccaagaagtacg 811

```

- 18 / 29 -

751 tcaagctgCGTTTCGAGCCAGTgcggggcctggaggctatctgtgccaag 800
|||||
812 tcaagctgCGTTTCGAGCCAGTgcggggcctggaggctatctgtgccaag 861
|||||
801 ttcacccacgagtcCCAGCGGCAGGAGAACCacttcgtggaagggctgct 850
|||||
862 ttcacccacgagtcCCAGCGGCAGGAGAACCacttcgtggaagggctgct 911
|||||
851 ctactccctggatgaggctgtcattatgacaggggtcatgacagatgagg 900
|||||
912 ctactccctggatgaggctgtcattatgacaggggtcatgacagatgagg 961
|||||
901 cagagcccagcaagctgaatagcattggcaattactacaagccgtgggtc 950
|||||
962 cagagcccagcaagctgaatagcattggcaattactacaagccgtgggtc 1011
|||||
951 tttAagcatgtggagaactatctgaagacaaaccgagagggcctggagta 1000
|||||
1012 tttAagcatgtggagaactatctgaagacaaaccgagagggcctggagta 1061
|||||
1001 cattcccttgagacactactaccacCGCCACACgcgcagcatcttctggg 1050
|||||
1062 cattcccttgagacactactaccacCGCCACACgcgcagcatcttctggg 1111
|||||
1051 agctccaggacatcatcccctttggcaacaaccccatcttccgctacctc 1100
|||||
1112 agctccaggacatcatcccctttggcaacaaccccatcttccgctacctc 1161
|||||
1101 tttggctggatggtgcctcccaagatctccctcctgaagctgaccaggg 1150
|||||
1162 tttggctggatggtgcctcccaagatctccctcctgaagctgaccaggg 1211
|||||
1151 tgagaccctgCGCAAG.tgtacgagcagcaccacgtggtgcaggacatgc 1199
|||||
1212 tgagaccctgCGCAAGctgtacgagcagcaccacgtggtgcaggacatgc 1261
|||||
1200 tggTgcccAtgaagtgcctgcagcaggccctgcacaccttccaaaacgac 1249
|||||
1262 tggTgcccAtgaagtgcctgcagcaggccctgcacaccttccaaaacgac 1311
|||||
1250 atccacgtctaccccatctggctgtgtccggttcatectgccagccagcc 1299
|||||
1312 atccacgtctaccccatctggctgtgtccggttcatectgccagccagcc 1361
|||||
1300 aggcctagtgcaccccaaaggaaatgaggcagagctctacatcgacattg 1349
|||||
1362 aggcctagtgcaccccaaaggaaatgaggcagagctctacatcgacattg 1411
|||||
1350 gagcatatggggagccgcgtgtgaaacactttgaagccaggtcctgcatg 1399
|||||
1412 gagcatatggggagccgcgtgtgaaacactttgaagccaggtcctgcatg 1461
|||||
1400 aggcagctggagaagtttgtccgcagcgtgcatggcttccagatgctgta 1449
|||||
1462 aggcagctggagaagtttgtccgcagcgtgcatggcttccagatgctgta 1511
|||||
1450 tgccgactgctacatgaaccgggaggagtctctgggagatgtttgatggct 1499
|||||
1512 tgccgactgctacatgaaccgggaggagtctctgggagatgtttgatggct 1561
|||||
1500 ccttgTaccacaagctgcgagagaagctgggttgccaggacgccttccc 1549
|||||
1562 ccttgTaccacaagctgcgagagaagctgggttgccaggacgccttccc 1611
|||||

- 19 / 29 -

1550 gaggtgtacgacaagatctgcaaggccgcccaggcactgagctggagcccg 1599
|||||
1612 gaggtgtacgacaagatctgcaaggccgcccaggcactgagctggagcccg 1661
1600 cctggagagacagacacgtgtgagtggtcaggcatcttcccttcaactcaa 1649
|||||
1662 cctggagagacagacacgtgtgagtggtcaggcatcttcccttcaactcaa 1711
1650 gcttggctgctttcctagatccacactttcaaagagaaaacccctccagaa 1699
|||||
1712 gcttggctgctttcctagatccacactttcaaagagaaaacccctccagaa 1761
1700 ctcccaccctgacagcccaacaccaccttcctcctggcttccagggggca 1749
|||||
1762 ctcccaccctgacagcccaacaccaccttcctcctggcttccagggggca 1811
1750 gccagtggaatggaaagaatgtgggatttgagtcagacaagcctgagt 1799
|||||
1812 gccagtggaatggaaagaatgtgggatttgagtcagacaagcctgagt 1861
1800 ccagttcccgttttagaactcattagctgtgtgactctgggtgagtcctt 1849
|||||
1862 ccagttcccgttttagaactcattagctgtgtgactctgggtgagtcctt 1911
1850 taaccctctgagcccggtctcttcattagttgaaaggatagtaatac 1899
|||||
1912 taaccctctgagcccggtctcttcattagttgaaaggatagtaatac 1961
1900 ctacttgacaggttggtgtcatctgagttgagcactggtcacattgaaggt 1949
|||||
1962 ctacttgacaggttggtgtcatctgagttgagcactggtcacattgaaggt 2011
1950 gctgggtaagtggtagctcttggtgcttcccgttcagcgtcacatctgca 1999
|||||
2012 gctgggtaagtggtagctcttggtgcttcccgttcagcgtcacatctgca 2061
2000 gtggagcctgaaaaggctccacattaggtcacctgtgcacagccatggct 2049
|||||
2062 gtggagcctgaaaaggctccacattaggtcacctgtgcacagccatggct 2111
2050 ggaatgatgaaggggatacgctggagttgccctgccatcgccctccatcag 2099
|||||
2112 ggaatgatgaaggggatacgctggagttgccctgccatcgccctccatcag 2161
2100 ccagacgaggtcctcacaggagaaggacagctcttccccaccctgggatc 2149
|||||
2162 ccagacgaggtcctcacaggagaaggacagctcttccccaccctgggatc 2211
2150 tcaggagggcagccacggagtggggaggccccagatgcgctgtgccaaag 2199
|||||
2212 tcaggagggcagccacggagtggggaggccccagatgcgctgtgccaaag 2261
2200 ccaggtccgaggccaaagtctccctgccatccttggtgccgtcctgccc 2249
|||||
2262 ccaggtccgaggccaaagtctccctgccatccttggtgccgtcctgccc 2311
2250 cttcctccttcatgcctgggcctgcaggcccacccagccaccactgagt 2299
|||||
2312 cttcctccttcatgcctgggcctgcaggcccacccagccaccactgagt 2361
2300 ccactcggagtgccctgtgttctctggagaaggcattccagggttgaatct 2349
|||||
2362 ccactcggagtgccctgtgttctctggagaaggcattccagggttgaatct 2411

- 20 / 29 -

2350 tgtcccagcctcagcctgggacacctaggtggagagagtggctctccgctc 2399
|||||
2412 tgtcccagcctcagcctgggacacctaggtggagagagtggctctccgctc 2461
|||||
2400 tgaattggatccaggggacctgggctcattcttcttggctcaccaaccct 2449
|||||
2462 tgaattggatccaggggacctgggctcattcttcttggctcaccaaccct 2511
|||||
2450 gcaggcctcatctttcccaaaacccactttgtcttgggtgggagtgggtcc 2499
|||||
2512 gcaggcctcatctttcccaaaacccactttgtcttgggtgggagtgggtcc 2561
|||||
2500 gcgctgctctgcagcaggggctggggagtggacagcatcaggtgggaaag 2549
|||||
2562 gcgctgctctgcagcaggggctggggagtggacagcatcaggtgggaaag 2611
|||||
2550 tggagtccaccctcatgtttctgtaggattctcaccgtggggctggaaga 2599
|||||
2612 tggagtccaccctcatgtttctgtaggattctcaccgtggggctggaaga 2661
|||||
2600 aaagagcatcgacttgatttctccaaccactcatccctctttttctttct 2649
|||||
2662 aaagagcatcgacttgatttctccaaccactcatccctctttttctttct 2711
|||||
2650 tccaccactccccacccagctgtagttaatttcagtgccctacaaatcc 2699
|||||
2712 tccaccactccccacccagctgtagttaatttcagtgccctacaaatcc 2761
|||||
2700 taagctcagagaaagtccatttccgttccagagggaagggaacctccct 2749
|||||
2762 taagctcagagaaagtccatttccgttccagagggaagggaacctccct 2811
|||||
2750 aggtccttcctggcttggttataacgcaaagcttggttggttatgcaact 2799
|||||
2812 aggtccttcctggcttggttataacgcaaagcttggttggttatgcaact 2861
|||||
2800 ctatcttaagaactgccagcctcagctgaaaacccgaatctgagaagga 2849
|||||
2862 ctatcttaagaactgccagcctcagctgaaaacccgaatctgagaagga 2911
|||||
2850 attgcgctcatgtaagggaagctggaattaaggagctgagccagtcattg 2899
|||||
2912 attgcgctcatgtaagggaagctggaattaaggagctgagccagtcattg 2961
|||||
2900 ttgtggcgtgtgagtcaggagacctaggtttcagcccctctctactgtca 2949
|||||
2962 ttgtggcgtgtgagtcaggagacctaggtttcagcccctctctactgtca 3011
|||||
2950 gcgagctgtgcaacgtgggcaagtcattgtcctctgagctgcagtttcct 2999
|||||
3012 gcgagctgtgcaacgtgggcaagtcattgtcctctgagctgcagtttcct 3061
|||||
3000 catctgtcacatcgctacagacaagacctccctggaacccttctgattgt 3049
|||||
3062 catctgtcacatcgctacagacaagacctccctggaacccttctgattgt 3111
|||||
3050 cttagacactgtggttgcaaaacccacggaagcctcatttgtgtggaaa 3099
|||||
3112 cttagacactgtggttgcaaaacccacggaagcctcatttgtgtggaaa 3161
|||||
3100 gtcagaggaaaaatgatccagtggaacttggggattatctgtcattcaa 3149
|||||
3162 gtcagaggaaaaatgatccagtggaacttggggattatctgtcattcaa 3211
|||||

- 21 / 29 -

3150 gatccttccttcaacccaaggccagctcccatctcatttccagaaaggc 3199
|||||
3212 gatccttccttcaacccaaggccagctcccatctcatttccagaaaggc 3261
3200 tcatacctggcttgaggggaagcatctgtcttggtcattccaggtgccaga 3249
|||||
3262 tcatacctggcttgaggggaagcatctgtcttggtcattccaggtgccaga 3311
3250 atcctctcagagtcattgaagggtgttcacccatcccacccaaggcttgg 3299
|||||
3312 atcctctcagagtcattgaagggtgttcacccatcccacccaaggcttgg 3361
3300 cacactgccagtgtcttagcaggggtcttgtaggggtgggggcatccagg 3349
|||||
3362 cacactgccagtgtcttagcaggggtcttgtaggggtgggggcatccagg 3411
3350 cactcagaaggcaaaggaaccaccctaccatttggcctctggagggggc 3399
|||||
3412 cactcagaaggcaaaggaaccaccctaccatttggcctctggagggggc 3461
3400 agaagaaagaaagaaacctcatcctatatattttacaaagcatgtgaattct 3449
|||||
3462 agaagaaagaaagaaacctcatcctatatattttacaaagcatgtgaattct 3511
3450 ggcattagctctcataggagaccatgtgcttccttgctcagtgcataaac 3499
|||||
3512 ggcattagctctcataggagaccatgtgcttccttgctcagtgcataaac 3561
3500 tgatgattctacttgctgtagatgaatgggtaaacacgagctagttaaaca 3549
|||||
3562 tgatgattctacttgctgtagatgaatgggtaaacacgagctagttaaaca 3611
3550 gtgccattgttttgccagtgaagcctccaaccctaagccactgggacggt 3599
|||||
3612 gtgccattgttttgccagtgaagcctccaaccctaagccactgggacggt 3661
3600 ggccagagatgccagcagcctctgtcgcccttagtcatataacaaaaatc 3649
|||||
3662 ggccagagatgccagcagcctctgtcgcccttagtcatataacaaaaatc 3711
3650 cagaccttatccacaacccggggcttggaaggaagggtattttggaatca 3699
|||||
3712 cagaccttatccacaacccggggcttggaaggaagggtattttggaatca 3761
3700 caccctccggttatgttgctccagtaaaatcttgccctggaaagaggcagt 3749
|||||
3762 caccctccggttatgttgctccagtaaaatcttgccctggaaagaggcagt 3811
3750 cttcttagcatgggtgagctgagttcatggcttttttttagccagtcct 3799
|||||
3812 cttcttagcatgggtgagctgagttcatggcttttttttagccagtcct 3861
3800 gtccctggccatccatgtgatgggttttgatggaggttaaacttgatgcc 3849
|||||
3862 gtccctggccatccatgtgatgggttttgatggaggttaaacttgatgcc 3911
3850 gtgggcagtgcatgtggaagtatcagagtaagcctctcccctccagagc 3899
|||||
3912 gtgggcagtgcatgtggaagtatcagagtaagcctctcccctccagagc 3961
3900 cctgagtttcttggtgcatgaagggttttctttagaatcagaattgtagc 3949
|||||
3962 cctgagtttcttggtgcatgaagggttttctttagaatcagaattgtagc 4011

- 22 / 29 -

```
3950 cagtttctttggccagaaggatgaatacttggatattactgaaagggagg 3999
      |||
4012 cagtttctttggccagaaggatgaatacttggatattactgaaagggagg 4061
      |||
4000 ggtggagatgggtgtggcagtgatggtgtgtgatttttattttcttctt 4049
      |||
4062 ggtggagatgggtgtggcagtgatggtgtgtgatttttattttcttctt 4111
      |||
4050 tggatcatgggggccaaggagaaaggcatgaatcttccctgtcaggctctt 4099
      |||
4112 tggatcatgggggccaaggagaaaggcatgaatcttccctgtcaggctctt 4161
      |||
4100 acagccacaggcactgtgtctactgtctggaagacatgtccccgtggctg 4149
      |||
4162 acagccacaggcactgtgtctactgtctggaagacatgtccccgtggctg 4211
      |||
4150 tggggccgctgcttctgtttaaataaaaagtggcctgg 4186
      |||
4212 tggggccgctgcttctgtttaaataaaaagtggcctgg 4248
```

- 23 / 29 -

Fig. 16

1 MEPAVSLAVC ALLFLLWVRL KGLEFVLIHQ RWFVCLLEL PLSLIEDIYY
 51 YVRAWVFKL SSAPRLHEQR VRDIQQVRE WKEQGSKTEM CTGRPGWLTV
 101 SLRVGKYKKT HKNIMINIMD ^{*}ILEVDTKKQI VRVEPLVTMG QVTALLTSIG
 151 WTLPLPELD DLTVGGLIMG TGLESSHKY GLEQHICTAY ELVLADGSEV
 201 RCTPSENSDL FYAVPWSCGT LGFLVAAEIR IIPAKKYVKL RFEPVRGLEA
 251 ICAKFTHEsq RQENHFVEGL LYSLEAVIM TGVMTDEAEP SKLNSIGNYY
 301 KPWFFKHVEN YLKTNRGLE YIPLRHYHR HTRSIFWELQ DIIPFGNNPI
 351 FRYLFQWMP PKISLLKLTQ GETLRKLYEQ ^{*}HHVVQDMLVP MKCLQQALHT
 401 FQNDIHVYPI WLCPFILPSQ PGLVHPKGNE AELYIDIGAY GEPRVKHFEA
 451 RSCMRQLEKF VRSVHGQML YADCYMNREE FWEMFDGSLY HKLREKLGCCQ
 501 DAFPEVYDKI CKAARH

- 24 / 29 -




Fig. 17 A




Fig. 17 B

- 26 / 29 -




Fig. 18

- 27 / 29 -





Fig. 19

Fig. 20






Fig. 21

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/08744

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12Q1/68 G01N33/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Emhum2 Database Entry Hsrsc390 Accession number D13643; 31 March 1993 NOMURA N.: "Human mRNA for KIAA0018 gene, complete cds." XP002099607 the whole document -& NOBUO NOMURA ET AL.: "Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1" DNA RESEARCH, vol. 1, no. 1, 1994, pages 27-35, XP002099608 abstract; tables 3,4 -& NOBUO NOMURA ET AL.: "Prediction of the coding sequences of unidentified human -/-	5,8-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 March 2000

Date of mailing of the international search report

10/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/EP 99/08744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1 (Supplement)" DNA RESEARCH, vol. 1, no. 1, 1994, pages 47-56, XP002065816 the whole document	
A	EP 0 814 157 A (SMITHKLINE-BEECHAM CORPORATION) 29 December 1997 (1997-12-29) page 3, line 40 -page 9, line 32	1-27, 35-38
T	GREEVE, I. (1) ET AL: "Expression of Seladin -1, a novel neuroprotective gene with homologies to oxido-reductases is associated with selective vulnerability in Alzheimer's disease." SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1999) VOL. 25, NO. 1-2, PP. 546. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 THE SOCIETY FOR NEUROSCIENC. , XP002134188	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/08744

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
28-34 and partially 21-27 and 35-38
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 28-34 and partially 21-27 and 35-38

Present claims 21-38 relate to a compound defined by reference to a desirable characteristic or property, namely affecting a level, an activity or both of a substance selected from the group of (a) to (f) as defined in the above mentioned claims. The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any specific example of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products defined as (a) to (f) for claims 21-27 and 35-38, while no search has been carried out for claims 28-34.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 814157 A	29-12-1997	JP 10210970 A	11-08-1998